Menu
15/02/2006
Woman loses Herceptin treatment case
A woman being treated for breast cancer has lost a court battle to get the anti-cancer drug Herceptin prescribed on the NHS.
Ann Marie Rodgers, 53, had taken the case when she was refused the drug by the Swindon Primary Care Trust (PCT), but a court today ruled that the Trust has been acting within the law in its refusal to prescribe the drug to Mrs Rogers.
Mrs Rogers' legal team lodged an appeal against the ruling which was granted. She has been paying to receive the drug, which is not licensed for early-stage breast cancer. An her legal team are seeking an order that would enable her to receive the drug until the appeal case is heard.
Mrs Rogers solicitor Yogi Amin said his client was bitterly disappointed by the decision.
Speaking outside the court, Mr Amin said: She felt it was common sense that a policy to refuse to provide treatment, where other authorities are providing it, should be struck down."
Mr Amin said the ordeal for Mrs Rogers was a "fight for her life".
Mr Justice Bean, ruling that the Trust had not acted illegally, said: "The court's task is not to say which policy is better, but to decide whether Swindon's policy is arbitrary or irrational, and thus unlawful.
"Accordingly, despite my sympathy for Mrs Rogers plight, I must dismiss the claim for judicial review."
The case is understood to be the first of its kind.
Herceptin has been licensed for use in late stage breast cancer, but despite mounting evidence indicating that the drug may be beneficial in early-stage breast cancer, the drug must be approved for such use after a full assessment by the National Institute for Health and Clinical Excellence (NICE).
Herceptin is one of a number of drugs that are currently being assessed by NICE to determine the benefits of treatment.
A course of the drug costs in the region of £20,000 a year, and although a number of Trusts had declined courses, the decisions had been reversed before the cases reached court.
A spokepeson for Swindon PCT said that the trust had to consider all its patients when making decisions on treatment policies.
Responding to today's court ruling, Joanne Rule, the Chief Executive of patient support group CancerBACUP said: "This ruling has huge implications for cancer care. We believe the public will see this as postcode prescribing rather than local-decision making.
"The people who call our helpline want to know that decisions about their treatment depend on clinical need and not on where they live, how much money they have, or how "exceptional" they are in comparison to someone else."
She added: "The UK spends less on cancer treatments than other countries. In order to fund new treatments like this in future, we need proper planning as new treatments develop and a second national Cancer Plan with money attached to rebuild consensus about the future of cancer care in the UK."
(SP)
Ann Marie Rodgers, 53, had taken the case when she was refused the drug by the Swindon Primary Care Trust (PCT), but a court today ruled that the Trust has been acting within the law in its refusal to prescribe the drug to Mrs Rogers.
Mrs Rogers' legal team lodged an appeal against the ruling which was granted. She has been paying to receive the drug, which is not licensed for early-stage breast cancer. An her legal team are seeking an order that would enable her to receive the drug until the appeal case is heard.
Mrs Rogers solicitor Yogi Amin said his client was bitterly disappointed by the decision.
Speaking outside the court, Mr Amin said: She felt it was common sense that a policy to refuse to provide treatment, where other authorities are providing it, should be struck down."
Mr Amin said the ordeal for Mrs Rogers was a "fight for her life".
Mr Justice Bean, ruling that the Trust had not acted illegally, said: "The court's task is not to say which policy is better, but to decide whether Swindon's policy is arbitrary or irrational, and thus unlawful.
"Accordingly, despite my sympathy for Mrs Rogers plight, I must dismiss the claim for judicial review."
The case is understood to be the first of its kind.
Herceptin has been licensed for use in late stage breast cancer, but despite mounting evidence indicating that the drug may be beneficial in early-stage breast cancer, the drug must be approved for such use after a full assessment by the National Institute for Health and Clinical Excellence (NICE).
Herceptin is one of a number of drugs that are currently being assessed by NICE to determine the benefits of treatment.
A course of the drug costs in the region of £20,000 a year, and although a number of Trusts had declined courses, the decisions had been reversed before the cases reached court.
A spokepeson for Swindon PCT said that the trust had to consider all its patients when making decisions on treatment policies.
Responding to today's court ruling, Joanne Rule, the Chief Executive of patient support group CancerBACUP said: "This ruling has huge implications for cancer care. We believe the public will see this as postcode prescribing rather than local-decision making.
"The people who call our helpline want to know that decisions about their treatment depend on clinical need and not on where they live, how much money they have, or how "exceptional" they are in comparison to someone else."
She added: "The UK spends less on cancer treatments than other countries. In order to fund new treatments like this in future, we need proper planning as new treatments develop and a second national Cancer Plan with money attached to rebuild consensus about the future of cancer care in the UK."
(SP)
Related UK National News Stories
Click here for the latest headlines.
17 June 2005
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
New drug raises hope of cancer treatment
A prototype cancer drug, which could help fight a range of cancers, has shown “promising results” in clinical trials. Scientists from the Institute of Cancer Research found that the 17AAG drug selectively and potently blocked the growth of a wide range of common cancer cells.
24 May 2005
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
Trials for prostate cancer drugs announced
Scientists have announced that they are testing new drugs that could be used to treat advanced prostate cancer. Currently, advanced prostate cancer is treated with hormone therapy. However, this only works for a short period of time, after which there are few other options for the patient, apart from palliative care.
21 June 2006
Government announces funding for drug treatment services
Drug treatment services across the country will receive an extra £95.2 million this year, under new plans announced by the government. The Department of Health, supported by £22 million of funding from the Home Office, will provide Drug Action Teams with £394.6 million - an increase of over 30% from last year.
Government announces funding for drug treatment services
Drug treatment services across the country will receive an extra £95.2 million this year, under new plans announced by the government. The Department of Health, supported by £22 million of funding from the Home Office, will provide Drug Action Teams with £394.6 million - an increase of over 30% from last year.
09 July 2003
Rise in crack users sent for treatment
More crack users are being targeted in custody and referred to drug treatment services, a new report published by the Home Office claims. The 'Arrest Referral' report shows that between October 2001 and September 2002, 12,014 crack users were interviewed, and of those 8,656 were referred to specialist drug treatment services - 18.
Rise in crack users sent for treatment
More crack users are being targeted in custody and referred to drug treatment services, a new report published by the Home Office claims. The 'Arrest Referral' report shows that between October 2001 and September 2002, 12,014 crack users were interviewed, and of those 8,656 were referred to specialist drug treatment services - 18.
13 June 2008
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
'Denied' Cancer Drug Now Available
A costly cancer drug that could have prolonged the life of a patient is now being made widely available in the UK. However, it is too late for charity-fund raiser, Jane Tomlinson, 43, who passed away last September. She was denied the drug, Lapatinib, because her NHS trust would not pay the £6,700 cost.
-
Northern Ireland WeatherThis Evening and Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
